TRACKING THE NOVEL CORONAVIRUS
At the end of Dec. 2019, scientists discovered a novel coronavirus infecting people in Wuhan City, China. About 2 months after its discovery, the virus, called SARS-CoV-2, had already spread to more than 70 countries, and its death toll had surpassed that of the 2003 severe acute respiratory syndrome outbreak. C&EN has made free its coverage of the race to understand and respond to the virus and the disease it causes, coronavirus disease 2019 (COVID-19). To learn more about how to prepare for the virus, please visit the US Centers for Disease Control and Prevention’s coronavirus page .”
Chemical makers brace for a slowdown on the continent
Podcast: How the coronavirus could disrupt the drug supply
Hear what C&EN’s pharmaceutical editors have learned about how the coronavirus is affecting drug production in China and across the globe
Chemists work around coronavirus restrictions
C&EN looks at how scientists are adapting to travel restrictions and working from home
Coronavirus forces cancellations of scientific meetings
Spring lineup of conferences and events frequented by chemists is slashed
ACS cancels spring national meeting in Philadelphia
Concerns over the spread of the novel coronavirus leads to decision
$8.3 billion allocated for US coronavirus response
Congress opts for open-ended support for federal and local agencies
Researchers in China report structure of the novel coronavirus bound to its human target
The structure shows the first steps of SARS-CoV-2 infection, and could help in drug discovery
Coronavirus cancels chemical events
Petrochemical and pharma meeting organizers say travel was becoming too difficult; ACS spring meeting is still on
Faulty probes are to blame for CDC coronavirus testing woes
The tests can still be used, CDC says, as urgency over possible outbreak grows
China’s new place on the front lines of diagnosing and treating coronavirus disease
Industry watchers say the effort is unprecedented and would not have been possible during the last SARS outbreak
Gilead and Moderna lead on coronavirus treatments
Gilead has a head start on an antiviral, while Moderna is pursuing a novel mRNA vaccine
Chemical firms see light at end of coronavirus tunnel
Facilities are reopening in China but spread of virus outside China is raising concerns
Diagnosing the novel coronavirus leads to trade offs
Medical workers in China weigh the advantages and disadvantages of nucleic acid lab tests and CT lung scans
Structure of novel coronavirus spike protein solved in just weeks
Cryo-EM structure of key coronavirus protein could help develop vaccines against the virus
Biotech firms consider contingency plans as the coronavirus outbreak hits CROs
The industry’s reliance on China-based firms for chemistry services is in the spotlight
What we do and don’t know about novel coronavirus
Scientists race to characterize, build vaccines and treatments for the virus as thousands fall ill
Novel coronavirus puts drug chemical industry on alert
Firms signal preparedness, but warn that prolonged plant closures and travel restrictions may cause significant disruption
Two groups use artificial intelligence to find compounds that could fight the novel coronavirus
One group identifies an existing drug, the other finds 6 novel molecules, but the consequences of reporting possibly helpful molecules are unclear
Coronavirus shadows China’s chemical industry
Executives in China and the US see a manageable crisis but also many unknowns
Drug firms mobilize to combat novel coronavirus outbreak
Development of diagnostics, vaccines, and treatments is underway
